Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

Posted by Defense World Staff on Jul 24th, 2024

Stock analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a report released on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $6.00 price target on shares of Cellectis in a research note on Friday, May 31st. Oppenheimer decreased their price target on shares of Cellectis from $11.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, June 12th.

Read Our Latest Stock Report on CLLS

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $2.07 on Wednesday. Cellectis has a twelve month low of $0.96 and a twelve month high of $3.77. The firm has a fifty day simple moving average of $2.34 and a 200 day simple moving average of $2.60. The company has a market capitalization of $115.05 million, a PE ratio of -1.60 and a beta of 3.11. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.69.

Cellectis (NASDAQ:CLLS – Get Free Report) last announced its earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) earnings per share for the quarter. Cellectis had a negative return on equity of 67.41% and a negative net margin of 529.81%. The firm had revenue of $6.50 million for the quarter. On average, sell-side analysts forecast that Cellectis will post -0.54 EPS for the current year.

Institutional Trading of Cellectis

An institutional investor recently raised its position in Cellectis stock. Principal Financial Group Inc. lifted its holdings in shares of Cellectis S.A. (NASDAQ:CLLS – Free Report) by 6.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 424,533 shares of the biotechnology company’s stock after purchasing an additional 24,906 shares during the period. Principal Financial Group Inc. owned about 0.76% of Cellectis worth $1,125,000 as of its most recent filing with the SEC. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Featured Articles

Receive News & Ratings for Cellectis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cellectis and related companies with MarketBeat.com’s FREE daily email newsletter.